Antipsihotic (Romanian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Antipsihotic" in Romanian language version.

refsWebsite

Global rank Romanian rank

83nih.gov

4^th place

78doi.org

2^nd place

3^rd place

28web.archive.org

1^st place

5books.google.com

3^rd place

6^th place

5choosingwisely.org

7,197^th place

7,686^th place

3nytimes.com

7^th place

25^th place

3nice.org.uk

3,258^th place

1,726^th place

2google.ca

838^th place

285^th place

2handle.net

102^nd place

537^th place

2google.co.uk

504^th place

245^th place

2psychiatryonline.org

4,032^nd place

6,156^th place

1worldcat.org

5^th place

11^th place

1who.int

195^th place

100^th place

1medscape.com

719^th place

901^st place

1ahrq.gov

9,469^th place

7,282^nd place

1archive.is

87^th place

68^th place

1bmj.com

1,226^th place

1,215^th place

1drugs.com

399^th place

157^th place

1harvard.edu

18^th place

27^th place

1rcpsych.org

low place

1oxfordjournals.org

1,389^th place

452^nd place

1archive.today

14^th place

121^st place

1wkhealth.com

low place

1psychiatrist.com

low place

1ub.edu

4,184^th place

3,159^th place

1uni.lu

low place

1oed.com

360^th place

751^st place

1springerlink.com

2,569^th place

698^th place

1theguardian.com

12^th place

74^th place

1bbc.co.uk

8^th place

14^th place

1reuters.com

49^th place

124^th place

1washingtonpost.com

34^th place

147^th place

1uow.edu.au

6,834^th place

low place

ahrq.gov

archive.ahrq.gov

„Evidence Lacking to Support Many Off-label Uses of Atypical Antipsychotics” (Press release). Agency for Healthcare Research and Quality. 17 ianuarie 2007. Arhivat din originalul de la 25 februarie 2013. Accesat în 29 iulie 2013.

archive.is

Barry SJ, Gaughan TM, Hunter R (Iunie 2012). „Schizophrenia”. BMJ Clinical Evidence. 2012. PMC 3385413 . PMID 23870705. Arhivat din original la 21-09-2014. Verificați datele pentru: |date=, |archive-date= (ajutor)

archive.today

Swainston Harrison T, Perry CM (2004). „Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder”. Drugs. 64 (15): 1715–36. doi:10.2165/00003495-200464150-00010. PMID 15257633. Arhivat din original la 10-07-2012. Verificați datele pentru: |archive-date= (ajutor)

bbc.co.uk

news.bbc.co.uk

Nick Triggle (12 noiembrie 2009). „Dementia drug use 'killing many'”. BBC. Arhivat din originalul de la 26 aprilie 2013. Accesat în 7 mai 2013. Verificați datele pentru: |access-date= (ajutor)

bmj.com

clinicalevidence.bmj.com

Barry SJ, Gaughan TM, Hunter R (Iunie 2012). „Schizophrenia”. BMJ Clinical Evidence. 2012. PMC 3385413 . PMID 23870705. Arhivat din original la 21-09-2014. Verificați datele pentru: |date=, |archive-date= (ajutor)

books.google.com

Finkel RF, Clark MA, Cubeddu LX (2009). Pharmacology (în engleză). Lippincott Williams & Wilkins. p. 151. ISBN 9780781771559. Arhivat din originalul de la 1 aprilie 2017.
American Psychiatric Association and American Psychiatric Association. Work Group on Borderline Personality Disorder (2001). Practice Guideline for the Treatment of Patients With Borderline Personality Disorder. American Psychiatric Pub. p. 4. ISBN 978-0890423196. Accesat în 5 iunie 2013.
Moore DP, Puri BK (2012). Textbook of Clinical Neuropsychiatry and Behavioral Neuroscience, Third Edition (în engleză). CRC Press. p. 791. ISBN 9781444164947. Arhivat din originalul de la 25 noiembrie 2017.
Owens DG (13 aprilie 1999). A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge University Press. p. 12. ISBN 978-0-521-63353-6. Arhivat din originalul de la 18 martie 2016.
Ayd, Frank J. (2000). „neuroleptic”. Lexicon of Psychiatry, Neurology, and the Neurosciences (în engleză). Lippincott Williams & Wilkins. p. 675. ISBN 9780781724685.

choosingwisely.org

„American Psychiatric Association Five Things Physicians and Patients Should Question”. Choosing Wisely. Arhivat din originalul de la 3 decembrie 2013. Accesat în 23 septembrie 2013.
AMDA – The Society for Post-Acute and Long-Term Care Medicine (februarie 2014), „Ten Things Physicians and Patients Should Question”, Choosing Wisely: an initiative of the ABIM Foundation, AMDA – The Society for Post-Acute and Long-Term Care Medicine, arhivat din originalul de la 13 septembrie 2014, accesat în 20 aprilie 2015 .
American Psychiatric Association (septembrie 2013), „Five Things Physicians and Patients Should Question”, Choosing Wisely: an initiative of the ABIM Foundation, American Psychiatric Association, arhivat din originalul de la 3 decembrie 2013, accesat în 30 decembrie 2013 , which cites
- Association, American Psychiatric (2006). Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition. 1. doi:10.1176/appi.books.9780890423363.45859. ISBN 978-0-89042-336-3.
- American Psychiatric Association (Septembrie 2013), „Five Things Physicians and Patients Should Question”, Choosing Wisely: an initiative of the ABIM Foundation, American Psychiatric Association, arhivat din originalul de la 3 decembrie 2013, accesat în 30 decembrie 2013 Verificați datele pentru: |date= (ajutor), care citează
  - Association, American Psychiatric (2006). „Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias, Second Edition”. APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches. 1. doi:10.1176/appi.books.9780890423967.152139. ISBN 978-0-89042-336-3.
  - American Geriatrics Society, „Ten Things Physicians and Patients Should Question”, Choosing Wisely: an initiative of the ABIM Foundation, American Geriatrics Society, arhivat din originalul de la 1 septembrie 2013, accesat în 1 august 2013 , which cites
    - American Geriatrics Society 2012 Beers Criteria Update Expert Panel (Aprilie 2012). „American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults”. Journal of the American Geriatrics Society. 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677 . PMID 22376048. Verificați datele pentru: |date= (ajutor)

doi.org

Hippius, H. (1 martie 1989). „The history of clozapine”. Psychopharmacology (în engleză). 99 (1): S3–S5. doi:10.1007/BF00442551. ISSN 0033-3158.
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (Ianuarie 2009). „Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis”. Lancet. 373 (9657): 31–41. doi:10.1016/S0140-6736(08)61764-X. PMID 19058842. Verificați datele pentru: |date= (ajutor)
Goikolea JM, Colom F, Torres I, Capapey J, Valentí M, Undurraga J, Grande I, Sanchez-Moreno J, Vieta E (ianuarie 2013). „Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol”. Journal of Affective Disorders. 144 (3): 191–8. doi:10.1016/j.jad.2012.07.038. PMID 23089129.
Barnes TR (Mai 2011). „Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology”. Journal of Psychopharmacology. 25 (5): 567–620. doi:10.1177/0269881110391123. PMID 21292923. Verificați datele pentru: |date= (ajutor)
Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (Decembrie 2012). „Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents”. Molecular Psychiatry. 17 (12): 1206–27. doi:10.1038/mp.2012.47. PMID 22584864. Verificați datele pentru: |date= (ajutor)
Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS (Octombrie 2012). „Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis”. Annals of Internal Medicine. 157 (7): 498–511. doi:10.7326/0003-4819-157-7-201210020-00525. PMID 22893011. Verificați datele pentru: |date= (ajutor)
Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A, Leucht S (Ianuarie 2015). „Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies”. JAMA Psychiatry. 72 (1): 14–21. doi:10.1001/jamapsychiatry.2014.2127. PMID 25372935. Verificați datele pentru: |date= (ajutor)
Keefe RS, Silva SG, Perkins DO, Lieberman JA (01-01-1999). „The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis”. Schizophrenia Bulletin. 25 (2): 201–22. doi:10.1093/oxfordjournals.schbul.a033374. PMID 10416727. Verificați datele pentru: |date= (ajutor)
Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (Aprilie 2009). „How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials”. Molecular Psychiatry. 14 (4): 429–47. doi:10.1038/sj.mp.4002136. PMID 18180760. Verificați datele pentru: |date= (ajutor)
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (Septembrie 2013). „Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis”. Lancet. 382 (9896): 951–62. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. Verificați datele pentru: |date= (ajutor)
Beitinger R, Lin J, Kissling W, Leucht S (Octombrie 2008). „Comparative remission rates of schizophrenic patients using various remission criteria”. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32 (7): 1643–51. doi:10.1016/j.pnpbp.2008.06.008. PMID 18616969. Verificați datele pentru: |date= (ajutor)
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM (MaI 2012). „Maintenance treatment with antipsychotic drugs for schizophrenia”. The Cochrane Database of Systematic Reviews. 5 (5): CD008016. doi:10.1002/14651858.CD008016.pub2. PMID 22592725. Verificați datele pentru: |date= (ajutor)
Kinon BJ, Ascher-Svanum H, Adams DH, Chen L (Octombrie 2008). „The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials”. Journal of Clinical Psychopharmacology. 28 (5): 544–9. doi:10.1097/JCP.0b013e318185e74a. PMID 18794651. Verificați datele pentru: |date= (ajutor)
Correll CU, Sheridan EM, DelBello MP (Martie 2010). „Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials”. Bipolar Disorders. 12 (2): 116–41. doi:10.1111/j.1399-5618.2010.00798.x. PMID 20402706. Verificați datele pentru: |date= (ajutor)
Tohen M, Katagiri H, Fujikoshi S, Kanba S (iulie 2013). „Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies”. Journal of Affective Disorders. 149 (1–3): 196–201. doi:10.1016/j.jad.2013.01.022. PMID 23485111.
Thase ME (Februarie 2008). „Quetiapine monotherapy for bipolar depression”. Neuropsychiatric Disease and Treatment. 4 (1): 11–21. doi:10.2147/ndt.s1162. PMC 2515925 . PMID 18728771. Verificați datele pentru: |date= (ajutor)
Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL (iulie 2005). „Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial”. The American Journal of Psychiatry. 162 (7): 1281–90. doi:10.1176/appi.ajp.162.7.1281. PMID 15994710.
Duffy A, Milin R, Grof P (Februarie 2009). „Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine”. BMC Psychiatry. 9: 4. doi:10.1186/1471-244X-9-4. PMC 2644292 . PMID 19200370. Verificați datele pentru: |date= (ajutor)
Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B (noiembrie 2011). „Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study)”. The Journal of Clinical Psychiatry. 72 (11): 1452–64. doi:10.4088/JCP.11m06878. PMID 22054050.
Cipriani A, Rendell JM, Geddes J (Ianuarie 2009). Cipriani A, ed. „Olanzapine in long-term treatment for bipolar disorder”. The Cochrane Database of Systematic Reviews (1): CD004367. doi:10.1002/14651858.CD004367.pub2. PMID 19160237. Verificați datele pentru: |date= (ajutor)
Ballard C, Waite J (ianuarie 2006). Ballard CG, ed. „The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease”. The Cochrane Database of Systematic Reviews (1): CD003476. doi:10.1002/14651858.CD003476.pub2. PMID 16437455.
Richter T, Meyer G, Möhler R, Köpke S (Decembrie 2012). Köpke S, ed. „Psychosocial interventions for reducing antipsychotic medication in care home residents”. The Cochrane Database of Systematic Reviews. 12: CD008634. doi:10.1002/14651858.CD008634.pub2. PMID 23235663. Verificați datele pentru: |date= (ajutor)
Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (Decembrie 2010). „Second-generation antipsychotics for major depressive disorder and dysthymia”. The Cochrane Database of Systematic Reviews (12): CD008121. doi:10.1002/14651858.CD008121.pub2. PMID 21154393. Verificați datele pentru: |date= (ajutor)
Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013). „Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes”. PLoS Medicine. 10 (3): e1001403. doi:10.1371/journal.pmed.1001403. PMC 3595214 . PMID 23554581.
Maher AR, Theodore G (Iunie 2012). „Summary of the comparative effectiveness review on off-label use of atypical antipsychotics”. Journal of Managed Care Pharmacy. 18 (5 Suppl B): S1–20. doi:10.18553/jmcp.2012.18.s5-b.1. PMID 22784311. Verificați datele pentru: |date= (ajutor)
Coe HV, Hong IS (Mai 2012). „Safety of low doses of quetiapine when used for insomnia”. The Annals of Pharmacotherapy. 46 (5): 718–22. doi:10.1345/aph.1Q697. PMID 22510671. Verificați datele pentru: |date= (ajutor)
Zuddas A, Zanni R, Usala T (august 2011). „Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies”. European Neuropsychopharmacology. 21 (8): 600–20. doi:10.1016/j.euroneuro.2011.04.001. PMID 21550212.
Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, Sandor P (Martie 2012). „Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy”. Canadian Journal of Psychiatry. 57 (3): 133–43. doi:10.1177/070674371205700302. PMID 22397999. Verificați datele pentru: |date= (ajutor)
McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J (Mai 2011). „A systematic review of medical treatments for children with autism spectrum disorders”. Pediatrics. 127 (5): e1312–21. doi:10.1542/peds.2011-0427. PMID 21464191. Verificați datele pentru: |date= (ajutor)
James AC (2010). „Prescribing antipsychotics for children and adolescents”. Advances in Psychiatric Treatment. 16 (1): 63–75. doi:10.1192/apt.bp.108.005652.
Posey DJ, Stigler KA, Erickson CA, McDougle CJ (Ianuarie 2008). „Antipsychotics in the treatment of autism”. The Journal of Clinical Investigation. 118 (1): 6–14. doi:10.1172/JCI32483. PMC 2171144 . PMID 18172517. Verificați datele pentru: |date= (ajutor)
Romeo R, Knapp M, Tyrer P, Crawford M, Oliver-Africano P (Iulie 2009). „The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis”. Journal of Intellectual Disability Research. 53 (7): 633–43. doi:10.1111/j.1365-2788.2009.01180.x. PMID 19460067. Verificați datele pentru: |date= (ajutor)
Linton, D; Barr, AM; Honer, WG; Procyshyn, RM (Mai 2013). „Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability”. Current psychiatry reports. 15 (5): 355. doi:10.1007/s11920-013-0355-6. PMID 23539465. Verificați datele pentru: |date= (ajutor)
Taylor DM, Duncan-McConnell D (2000). „Refractory schizophrenia and atypical antipsychotics”. Journal of Psychopharmacology. 14 (4): 409–18. doi:10.1177/026988110001400411. PMID 11198061.
Essali A, Al-Haj Haasan N, Li C, Rathbone J (Ianuarie 2009). „Clozapine versus typical neuroleptic medication for schizophrenia”. The Cochrane Database of Systematic Reviews (1): CD000059. doi:10.1002/14651858.CD000059.pub2. PMID 19160174. Verificați datele pentru: |date= (ajutor)
Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (Februarie 2006). „Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics”. The American Journal of Psychiatry. 163 (2): 185–94. doi:10.1176/appi.ajp.163.2.185. PMID 16449469. Verificați datele pentru: |date= (ajutor)
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (Septembrie 2005). „Effectiveness of antipsychotic drugs in patients with chronic schizophrenia”. The New England Journal of Medicine. 353 (12): 1209–23. doi:10.1056/NEJMoa051688. PMID 16172203. Verificați datele pentru: |date= (ajutor)
Voruganti LP, Baker LK, Awad AG (martie 2008). „New generation antipsychotic drugs and compliance behaviour”. Current Opinion in Psychiatry. 21 (2): 133–9. doi:10.1097/YCO.0b013e3282f52851. PMID 18332660.
Paczynski RP, Alexander GC, Chinchilli VM, Kruszewski SP (Ianuarie 2012). „Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications”. The International Journal of Risk & Safety in Medicine. 24 (3): 137–46. doi:10.3233/JRS-2012-0567. PMID 22936056. Verificați datele pentru: |date= (ajutor)
Owens, D. C. (2008). „How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia”. Advances in Psychiatric Treatment. 14 (1): 17–28. doi:10.1192/apt.bp.107.003970.
Fischer-Barnicol D, Lanquillon S, Haen E, Zofel P, Koch HJ, Dose M, Klein HE (2008). „Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE)”. Neuropsychobiology. 57 (1–2): 80–7. doi:10.1159/000135641. PMID 18515977.
Casey DE (martie 1999). „Tardive dyskinesia and atypical antipsychotic drugs”. Schizophrenia Research. 35 (Suppl 1): S61–6. doi:10.1016/S0920-9964(98)00160-1. PMID 10190226.
Makhinson M (Ianuarie 2010). „Biases in medication prescribing: the case of second-generation antipsychotics”. Journal of Psychiatric Practice. 16 (1): 15–21. doi:10.1097/01.pra.0000367774.11260.e4. PMID 20098227. Verificați datele pentru: |date= (ajutor)
American Psychiatric Association (septembrie 2013), „Five Things Physicians and Patients Should Question”, Choosing Wisely: an initiative of the ABIM Foundation, American Psychiatric Association, arhivat din originalul de la 3 decembrie 2013, accesat în 30 decembrie 2013 , which cites
- Association, American Psychiatric (2006). Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition. 1. doi:10.1176/appi.books.9780890423363.45859. ISBN 978-0-89042-336-3.
- Koller EA, Doraiswamy PM (Iulie 2002). „Olanzapine-associated diabetes mellitus”. Pharmacotherapy. 22 (7): 841–52. doi:10.1592/phco.22.11.841.33629. PMID 12126218. Verificați datele pentru: |date= (ajutor)
- Weston-Green K, Huang XF, Deng C (Februarie 2010). „Sensitivity of the female rat to olanzapine-induced weight gain--far from the clinic?”. Schizophrenia Research. 116 (2–3): 299–300. doi:10.1016/j.schres.2009.09.034. PMID 19840894. Verificați datele pentru: |date= (ajutor)
- Weston-Green K, Huang XF, Deng C (Februarie 2010). „Sensitivity of the female rat to olanzapine-induced weight gain--far from the clinic?”. Schizophrenia Research. 116 (2–3): 299–300. doi:10.1016/j.schres.2009.09.034. PMID 19840894. Verificați datele pentru: |date= (ajutor)
- Weston-Green K, Huang XF, Deng C (2012). Chang AY, ed. „Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain”. PLOS One. 7 (3): e33548. Bibcode:2012PLoSO...733548W. doi:10.1371/journal.pone.0033548. PMC 3306411 . PMID 22438946.
- Koller EA, Cross JT, Doraiswamy PM, Malozowski SN (Septembrie 2003). „Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports”. Pharmacotherapy. 23 (9): 1123–30. doi:10.1592/phco.23.10.1123.32759. PMID 14524644. Verificați datele pentru: |date= (ajutor)
- Weinmann S, Read J, Aderhold V (august 2009). „Influence of antipsychotics on mortality in schizophrenia: systematic review”. Schizophrenia Research. 113 (1): 1–11. doi:10.1016/j.schres.2009.05.018. PMID 19524406.
- Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V (Februarie 2006). „Schizophrenia, neuroleptic medication and mortality”. The British Journal of Psychiatry. 188 (2): 122–7. doi:10.1192/bjp.188.2.122. PMID 16449697. Verificați datele pentru: |date= (ajutor)
- American Geriatrics Society 2012 Beers Criteria Update Expert Panel (Aprilie 2012). „American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults”. Journal of the American Geriatrics Society. 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677 . PMID 22376048. Verificați datele pentru: |date= (ajutor)
- Medford N, Sierra M, Baker D, David A (2005). „Understanding and treating depersonalisation disorder”. Advances in Psychiatric Treatment. 11 (2): 92–100. doi:10.1192/apt.11.2.92. Arhivat din originalul de la 16 iulie 2011.
- Patrick V, Levin E, Schleifer S (Iulie 2005). „Antipsychotic polypharmacy: is there evidence for its use?”. Journal of Psychiatric Practice. 11 (4): 248–57. doi:10.1097/00131746-200507000-00005. PMID 16041235. Verificați datele pentru: |date= (ajutor)
- Ito H, Koyama A, Higuchi T (Septembrie 2005). „Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription”. The British Journal of Psychiatry. 187 (3): 243–7. doi:10.1192/bjp.187.3.243. PMID 16135861. Verificați datele pentru: |date= (ajutor)
- Vita A, De Peri L, Deste G, Sacchetti E (Noiembrie 2012). „Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies”. Translational Psychiatry. 2 (11): e190. doi:10.1038/tp.2012.116. PMC 3565772 . PMID 23168990. Verificați datele pentru: |date= (ajutor)
- Radua J, Borgwardt S, Crescini A, Mataix-Cols D, Meyer-Lindenberg A, McGuire PK, Fusar-Poli P (Noiembrie 2012). „Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication”. Neuroscience and Biobehavioral Reviews. 36 (10): 2325–33. doi:10.1016/j.neubiorev.2012.07.012. PMID 22910680. Verificați datele pentru: |date= (ajutor)
- Hirose S (2003). „The causes of underdiagnosing akathisia” (PDF). Schizophrenia Bulletin. 29 (3): 547–58. doi:10.1093/oxfordjournals.schbul.a007027. PMID 14609248. Arhivat (PDF) din originalul de la 15 octombrie 2015.
- Moncrieff J (Iulie 2006). „Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse”. Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. Verificați datele pentru: |date= (ajutor)
- Onrust SV, McClellan K (2001). „Perospirone”. CNS Drugs. 15 (4): 329–37; discussion 338. doi:10.2165/00023210-200115040-00006. PMID 11463136.
- Nemeroff CB, Lieberman JA, Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, Kilts CD, Daniel DG (noiembrie 2005). „From clinical research to clinical practice: a 4-year review of ziprasidone”. CNS Spectrums. 10 (11 Suppl 17): 1–20. doi:10.1017/S1092852900019842. PMID 16381088.
- Swainston Harrison T, Perry CM (2004). „Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder”. Drugs. 64 (15): 1715–36. doi:10.2165/00003495-200464150-00010. PMID 15257633. Arhivat din original la 10-07-2012. Verificați datele pentru: |archive-date= (ajutor)
- Pickar D, Litman RE, Konicki PE, Wolkowitz OM, Breier A (1990). „Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia”. Modern Problems of Pharmacopsychiatry. 24: 124–51. doi:10.1159/000418015. ISBN 978-3-8055-5050-5. PMID 1970851.
- Liemburg EJ, Knegtering H, Klein HC, Kortekaas R, Aleman A (Iunie 2012). „Antipsychotic medication and prefrontal cortex activation: a review of neuroimaging findings”. European Neuropsychopharmacology. 22 (6): 387–400. doi:10.1016/j.euroneuro.2011.12.008. PMID 22300864. Verificați datele pentru: |date= (ajutor)
- McDonald C, Murphy KC (Martie 2003). „The new genetics of schizophrenia”. The Psychiatric Clinics of North America. 26 (1): 41–63. doi:10.1016/S0193-953X(02)00030-8. PMID 12683259. Verificați datele pentru: |date= (ajutor)
- Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG (1995). „The role of 5-HT2A receptors in antipsychotic activity”. Life Sciences. 56 (25): 2209–22. doi:10.1016/0024-3205(95)00210-W. PMID 7791509.
- Gross G, Geyer MA (2012). Current Antipsychotics. Springer. pp. 88–89. doi:10.1007/978-3-642-25761-2. ISBN 978-3-642-25761-2.
- Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR (octombrie 2011). „Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis”. Lancet. 378 (9799): 1306–15. doi:10.1016/S0140-6736(11)60873-8. PMID 21851976.
- Citrome L (2013). „Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents”. Therapeutics and Clinical Risk Management. 9: 235–45. doi:10.2147/TCRM.S31484. PMC 3665578 . PMID 23723707.
- Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valentí M, Vieta E (februarie 2010). „Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis”. The International Journal of Neuropsychopharmacology. 13 (1): 5–14. doi:10.1017/S1461145709990344. hdl:2445/53243. PMID 19638254.
- Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E (mai 2012). „Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder”. European Neuropsychopharmacology. 22 (5): 339–46. doi:10.1016/j.euroneuro.2011.09.008. PMID 22000157.
- Vieta E, Günther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, Åström M, Paulsson B (Septembrie 2011). „Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials” (PDF). The International Journal of Neuropsychopharmacology. 14 (8): 1029–49. doi:10.1017/S1461145711000885. hdl:2445/51726. PMID 21733231. Arhivat (PDF) din originalul de la 18 august 2017. Verificați datele pentru: |date= (ajutor)
- Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (Decembrie 2010). „Second-generation antipsychotics for major depressive disorder and dysthymia”. The Cochrane Database of Systematic Reviews (12): CD008121. doi:10.1002/14651858.CD008121.pub2. PMID 21154393. Verificați datele pentru: |date= (ajutor)
- Kishi T, Iwata N (Septembrie 2013). „Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials”. CNS Drugs. 27 (9): 731–41. doi:10.1007/s40263-013-0085-7. PMID 23812802. Verificați datele pentru: |date= (ajutor)
- Pieters T, Majerus B (Decembrie 2011). „The introduction of chlorpromazine in Belgium and the Netherlands (1951-1968); tango between old and new treatment features”. Studies in History and Philosophy of Biological and Biomedical Sciences. 42 (4): 443–52. doi:10.1016/j.shpsc.2011.05.003. PMID 22035718. Arhivat din originalul de la 9 iulie 2017. Verificați datele pentru: |date= (ajutor)
- Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Höschl C (2006). „Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia”. CNS Drugs. 20 (5): 389–409. doi:10.2165/00023210-200620050-00004. PMID 16696579.
- American Psychiatric Association (Septembrie 2013), „Five Things Physicians and Patients Should Question”, Choosing Wisely: an initiative of the ABIM Foundation, American Psychiatric Association, arhivat din originalul de la 3 decembrie 2013, accesat în 30 decembrie 2013 Verificați datele pentru: |date= (ajutor), care citează
  - Association, American Psychiatric (2006). „Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias, Second Edition”. APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches. 1. doi:10.1176/appi.books.9780890423967.152139. ISBN 978-0-89042-336-3.
  - American Geriatrics Society, „Ten Things Physicians and Patients Should Question”, Choosing Wisely: an initiative of the ABIM Foundation, American Geriatrics Society, arhivat din originalul de la 1 septembrie 2013, accesat în 1 august 2013 , which cites
    - American Geriatrics Society 2012 Beers Criteria Update Expert Panel (Aprilie 2012). „American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults”. Journal of the American Geriatrics Society. 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677 . PMID 22376048. Verificați datele pentru: |date= (ajutor)

drugs.com

https://www.drugs.com/monograph/biperiden-hydrochloride.html Information for professionals about Biperiden at www.drugs.com

google.ca

books.google.ca

Haddad P, Haddad PM, Dursun S, Deakin B (2004). Adverse Syndromes and Psychiatric Drugs: A Clinical Guide (în engleză). OUP Oxford. pp. 207–216. ISBN 9780198527480.
Sacchetti E, Vita A, Siracusano A, Fleischhacker W (2013). Adherence to Antipsychotics in Schizophrenia (în engleză). Springer Science & Business Media. p. 85. ISBN 9788847026797.

google.co.uk

books.google.co.uk

Patel SC, Jakopac KA (2011). Manual of Psychiatric Nursing Skills (în engleză). Jones & Bartlett Publishers. p. 317. ISBN 9781449613563.
Drug Policy and the Public Good (în engleză). OUP Oxford. 2010. p. 329. ISBN 9780199557127.

handle.net

hdl.handle.net

Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valentí M, Vieta E (februarie 2010). „Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis”. The International Journal of Neuropsychopharmacology. 13 (1): 5–14. doi:10.1017/S1461145709990344. hdl:2445/53243. PMID 19638254.
Vieta E, Günther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, Åström M, Paulsson B (Septembrie 2011). „Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials” (PDF). The International Journal of Neuropsychopharmacology. 14 (8): 1029–49. doi:10.1017/S1461145711000885. hdl:2445/51726. PMID 21733231. Arhivat (PDF) din originalul de la 18 august 2017. Verificați datele pentru: |date= (ajutor)

harvard.edu

adsabs.harvard.edu

Weston-Green K, Huang XF, Deng C (2012). Chang AY, ed. „Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain”. PLOS One. 7 (3): e33548. Bibcode:2012PLoSO...733548W. doi:10.1371/journal.pone.0033548. PMC 3306411 . PMID 22438946.

medscape.com

Lowes R. „Lurasidone Approved for Bipolar Depression”. Medscape. Arhivat din originalul de la 2 octombrie 2013. Accesat în 2 octombrie 2013.

nice.org.uk

„NICE Treatment Guidance 2014”. Arhivat din originalul de la 13 august 2014. Accesat în 7 august 2014. Verificați datele pentru: |access-date= (ajutor)
The Royal College of Psychiatrists & The British Psychological Society (2003).Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care (PDF). London: Gaskell and the British Psychological Society.^{[necesită pagina]} Arhivat în 27 d.Hr., la Wayback Machine.

guidance.nice.org.uk

„Psychosis and schizophrenia in adults (CG178)”. Arhivat din originalul de la 4 martie 2014.

nih.gov

ncbi.nlm.nih.gov

King C, Voruganti LN (Mai 2002). „What's in a name? The evolution of the nomenclature of antipsychotic drugs”. Journal of Psychiatry & Neuroscience. 27 (3): 168–75. PMC 161646 . PMID 12066446. Verificați datele pentru: |date= (ajutor)
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (Ianuarie 2009). „Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis”. Lancet. 373 (9657): 31–41. doi:10.1016/S0140-6736(08)61764-X. PMID 19058842. Verificați datele pentru: |date= (ajutor)
Goikolea JM, Colom F, Torres I, Capapey J, Valentí M, Undurraga J, Grande I, Sanchez-Moreno J, Vieta E (ianuarie 2013). „Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol”. Journal of Affective Disorders. 144 (3): 191–8. doi:10.1016/j.jad.2012.07.038. PMID 23089129.
Barnes TR (Mai 2011). „Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology”. Journal of Psychopharmacology. 25 (5): 567–620. doi:10.1177/0269881110391123. PMID 21292923. Verificați datele pentru: |date= (ajutor)
Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (Decembrie 2012). „Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents”. Molecular Psychiatry. 17 (12): 1206–27. doi:10.1038/mp.2012.47. PMID 22584864. Verificați datele pentru: |date= (ajutor)
Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS (Octombrie 2012). „Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis”. Annals of Internal Medicine. 157 (7): 498–511. doi:10.7326/0003-4819-157-7-201210020-00525. PMID 22893011. Verificați datele pentru: |date= (ajutor)
Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A, Leucht S (Ianuarie 2015). „Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies”. JAMA Psychiatry. 72 (1): 14–21. doi:10.1001/jamapsychiatry.2014.2127. PMID 25372935. Verificați datele pentru: |date= (ajutor)
Keefe RS, Silva SG, Perkins DO, Lieberman JA (01-01-1999). „The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis”. Schizophrenia Bulletin. 25 (2): 201–22. doi:10.1093/oxfordjournals.schbul.a033374. PMID 10416727. Verificați datele pentru: |date= (ajutor)
Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (Aprilie 2009). „How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials”. Molecular Psychiatry. 14 (4): 429–47. doi:10.1038/sj.mp.4002136. PMID 18180760. Verificați datele pentru: |date= (ajutor)
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (Septembrie 2013). „Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis”. Lancet. 382 (9896): 951–62. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. Verificați datele pentru: |date= (ajutor)
Beitinger R, Lin J, Kissling W, Leucht S (Octombrie 2008). „Comparative remission rates of schizophrenic patients using various remission criteria”. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32 (7): 1643–51. doi:10.1016/j.pnpbp.2008.06.008. PMID 18616969. Verificați datele pentru: |date= (ajutor)
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM (MaI 2012). „Maintenance treatment with antipsychotic drugs for schizophrenia”. The Cochrane Database of Systematic Reviews. 5 (5): CD008016. doi:10.1002/14651858.CD008016.pub2. PMID 22592725. Verificați datele pentru: |date= (ajutor)
Kinon BJ, Ascher-Svanum H, Adams DH, Chen L (Octombrie 2008). „The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials”. Journal of Clinical Psychopharmacology. 28 (5): 544–9. doi:10.1097/JCP.0b013e318185e74a. PMID 18794651. Verificați datele pentru: |date= (ajutor)
Correll CU, Sheridan EM, DelBello MP (Martie 2010). „Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials”. Bipolar Disorders. 12 (2): 116–41. doi:10.1111/j.1399-5618.2010.00798.x. PMID 20402706. Verificați datele pentru: |date= (ajutor)
Tohen M, Katagiri H, Fujikoshi S, Kanba S (iulie 2013). „Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies”. Journal of Affective Disorders. 149 (1–3): 196–201. doi:10.1016/j.jad.2013.01.022. PMID 23485111.
Thase ME (Februarie 2008). „Quetiapine monotherapy for bipolar depression”. Neuropsychiatric Disease and Treatment. 4 (1): 11–21. doi:10.2147/ndt.s1162. PMC 2515925 . PMID 18728771. Verificați datele pentru: |date= (ajutor)
Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL (iulie 2005). „Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial”. The American Journal of Psychiatry. 162 (7): 1281–90. doi:10.1176/appi.ajp.162.7.1281. PMID 15994710.
Duffy A, Milin R, Grof P (Februarie 2009). „Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine”. BMC Psychiatry. 9: 4. doi:10.1186/1471-244X-9-4. PMC 2644292 . PMID 19200370. Verificați datele pentru: |date= (ajutor)
Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B (noiembrie 2011). „Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study)”. The Journal of Clinical Psychiatry. 72 (11): 1452–64. doi:10.4088/JCP.11m06878. PMID 22054050.
Cipriani A, Rendell JM, Geddes J (Ianuarie 2009). Cipriani A, ed. „Olanzapine in long-term treatment for bipolar disorder”. The Cochrane Database of Systematic Reviews (1): CD004367. doi:10.1002/14651858.CD004367.pub2. PMID 19160237. Verificați datele pentru: |date= (ajutor)
Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J (Februarie 2004). „Practice guideline for the treatment of patients with schizophrenia, second edition”. The American Journal of Psychiatry. 161 (2 Suppl): 1–56. PMID 15000267. Verificați datele pentru: |date= (ajutor)
Ballard C, Waite J (ianuarie 2006). Ballard CG, ed. „The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease”. The Cochrane Database of Systematic Reviews (1): CD003476. doi:10.1002/14651858.CD003476.pub2. PMID 16437455.
Richter T, Meyer G, Möhler R, Köpke S (Decembrie 2012). Köpke S, ed. „Psychosocial interventions for reducing antipsychotic medication in care home residents”. The Cochrane Database of Systematic Reviews. 12: CD008634. doi:10.1002/14651858.CD008634.pub2. PMID 23235663. Verificați datele pentru: |date= (ajutor)
Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (Decembrie 2010). „Second-generation antipsychotics for major depressive disorder and dysthymia”. The Cochrane Database of Systematic Reviews (12): CD008121. doi:10.1002/14651858.CD008121.pub2. PMID 21154393. Verificați datele pentru: |date= (ajutor)
Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013). „Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes”. PLoS Medicine. 10 (3): e1001403. doi:10.1371/journal.pmed.1001403. PMC 3595214 . PMID 23554581.
Maher AR, Theodore G (Iunie 2012). „Summary of the comparative effectiveness review on off-label use of atypical antipsychotics”. Journal of Managed Care Pharmacy. 18 (5 Suppl B): S1–20. doi:10.18553/jmcp.2012.18.s5-b.1. PMID 22784311. Verificați datele pentru: |date= (ajutor)
Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ (2011). Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Reviews, No. 43. Rockville: Agency for Healthcare Research and Quality. PMID 22973576.
Coe HV, Hong IS (Mai 2012). „Safety of low doses of quetiapine when used for insomnia”. The Annals of Pharmacotherapy. 46 (5): 718–22. doi:10.1345/aph.1Q697. PMID 22510671. Verificați datele pentru: |date= (ajutor)
Zuddas A, Zanni R, Usala T (august 2011). „Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies”. European Neuropsychopharmacology. 21 (8): 600–20. doi:10.1016/j.euroneuro.2011.04.001. PMID 21550212.
Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, Sandor P (Martie 2012). „Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy”. Canadian Journal of Psychiatry. 57 (3): 133–43. doi:10.1177/070674371205700302. PMID 22397999. Verificați datele pentru: |date= (ajutor)
McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J (Mai 2011). „A systematic review of medical treatments for children with autism spectrum disorders”. Pediatrics. 127 (5): e1312–21. doi:10.1542/peds.2011-0427. PMID 21464191. Verificați datele pentru: |date= (ajutor)
Posey DJ, Stigler KA, Erickson CA, McDougle CJ (Ianuarie 2008). „Antipsychotics in the treatment of autism”. The Journal of Clinical Investigation. 118 (1): 6–14. doi:10.1172/JCI32483. PMC 2171144 . PMID 18172517. Verificați datele pentru: |date= (ajutor)
Romeo R, Knapp M, Tyrer P, Crawford M, Oliver-Africano P (Iulie 2009). „The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis”. Journal of Intellectual Disability Research. 53 (7): 633–43. doi:10.1111/j.1365-2788.2009.01180.x. PMID 19460067. Verificați datele pentru: |date= (ajutor)
Linton, D; Barr, AM; Honer, WG; Procyshyn, RM (Mai 2013). „Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability”. Current psychiatry reports. 15 (5): 355. doi:10.1007/s11920-013-0355-6. PMID 23539465. Verificați datele pentru: |date= (ajutor)
Kane JM, Correll CU (2010). „Pharmacologic treatment of schizophrenia”. Dialogues in Clinical Neuroscience. 12 (3): 345–57. PMC 3085113 . PMID 20954430.
Barry SJ, Gaughan TM, Hunter R (Iunie 2012). „Schizophrenia”. BMJ Clinical Evidence. 2012. PMC 3385413 . PMID 23870705. Arhivat din original la 21-09-2014. Verificați datele pentru: |date=, |archive-date= (ajutor)
Schultz SH, North SW, Shields CG (Iunie 2007). „Schizophrenia: a review”. American Family Physician. 75 (12): 1821–9. PMID 17619525. Verificați datele pentru: |date= (ajutor)
Taylor DM, Duncan-McConnell D (2000). „Refractory schizophrenia and atypical antipsychotics”. Journal of Psychopharmacology. 14 (4): 409–18. doi:10.1177/026988110001400411. PMID 11198061.
Essali A, Al-Haj Haasan N, Li C, Rathbone J (Ianuarie 2009). „Clozapine versus typical neuroleptic medication for schizophrenia”. The Cochrane Database of Systematic Reviews (1): CD000059. doi:10.1002/14651858.CD000059.pub2. PMID 19160174. Verificați datele pentru: |date= (ajutor)
Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (Februarie 2006). „Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics”. The American Journal of Psychiatry. 163 (2): 185–94. doi:10.1176/appi.ajp.163.2.185. PMID 16449469. Verificați datele pentru: |date= (ajutor)
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (Septembrie 2005). „Effectiveness of antipsychotic drugs in patients with chronic schizophrenia”. The New England Journal of Medicine. 353 (12): 1209–23. doi:10.1056/NEJMoa051688. PMID 16172203. Verificați datele pentru: |date= (ajutor)
Voruganti LP, Baker LK, Awad AG (martie 2008). „New generation antipsychotic drugs and compliance behaviour”. Current Opinion in Psychiatry. 21 (2): 133–9. doi:10.1097/YCO.0b013e3282f52851. PMID 18332660.
Paczynski RP, Alexander GC, Chinchilli VM, Kruszewski SP (Ianuarie 2012). „Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications”. The International Journal of Risk & Safety in Medicine. 24 (3): 137–46. doi:10.3233/JRS-2012-0567. PMID 22936056. Verificați datele pentru: |date= (ajutor)
Fischer-Barnicol D, Lanquillon S, Haen E, Zofel P, Koch HJ, Dose M, Klein HE (2008). „Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE)”. Neuropsychobiology. 57 (1–2): 80–7. doi:10.1159/000135641. PMID 18515977.
Casey DE (martie 1999). „Tardive dyskinesia and atypical antipsychotic drugs”. Schizophrenia Research. 35 (Suppl 1): S61–6. doi:10.1016/S0920-9964(98)00160-1. PMID 10190226.
Makhinson M (Ianuarie 2010). „Biases in medication prescribing: the case of second-generation antipsychotics”. Journal of Psychiatric Practice. 16 (1): 15–21. doi:10.1097/01.pra.0000367774.11260.e4. PMID 20098227. Verificați datele pentru: |date= (ajutor)
Muench J, Hamer AM (martie 2010). „Adverse effects of antipsychotic medications”. American Family Physician. 81 (5): 617–22. PMID 20187598.
Lieberman JA (2004). „Managing anticholinergic side effects”. Primary Care Companion to the Journal of Clinical Psychiatry. 6 (Suppl 2): 20–3. PMC 487008 . PMID 16001097.
Koller EA, Doraiswamy PM (Iulie 2002). „Olanzapine-associated diabetes mellitus”. Pharmacotherapy. 22 (7): 841–52. doi:10.1592/phco.22.11.841.33629. PMID 12126218. Verificați datele pentru: |date= (ajutor)
Weston-Green K, Huang XF, Deng C (Februarie 2010). „Sensitivity of the female rat to olanzapine-induced weight gain--far from the clinic?”. Schizophrenia Research. 116 (2–3): 299–300. doi:10.1016/j.schres.2009.09.034. PMID 19840894. Verificați datele pentru: |date= (ajutor)
Weston-Green K, Huang XF, Deng C (Februarie 2010). „Sensitivity of the female rat to olanzapine-induced weight gain--far from the clinic?”. Schizophrenia Research. 116 (2–3): 299–300. doi:10.1016/j.schres.2009.09.034. PMID 19840894. Verificați datele pentru: |date= (ajutor)
Weston-Green K, Huang XF, Deng C (2012). Chang AY, ed. „Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain”. PLOS One. 7 (3): e33548. Bibcode:2012PLoSO...733548W. doi:10.1371/journal.pone.0033548. PMC 3306411 . PMID 22438946.
Koller EA, Cross JT, Doraiswamy PM, Malozowski SN (Septembrie 2003). „Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports”. Pharmacotherapy. 23 (9): 1123–30. doi:10.1592/phco.23.10.1123.32759. PMID 14524644. Verificați datele pentru: |date= (ajutor)
Weinmann S, Read J, Aderhold V (august 2009). „Influence of antipsychotics on mortality in schizophrenia: systematic review”. Schizophrenia Research. 113 (1): 1–11. doi:10.1016/j.schres.2009.05.018. PMID 19524406.
Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V (Februarie 2006). „Schizophrenia, neuroleptic medication and mortality”. The British Journal of Psychiatry. 188 (2): 122–7. doi:10.1192/bjp.188.2.122. PMID 16449697. Verificați datele pentru: |date= (ajutor)
American Geriatrics Society 2012 Beers Criteria Update Expert Panel (Aprilie 2012). „American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults”. Journal of the American Geriatrics Society. 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677 . PMID 22376048. Verificați datele pentru: |date= (ajutor)
Patrick V, Levin E, Schleifer S (Iulie 2005). „Antipsychotic polypharmacy: is there evidence for its use?”. Journal of Psychiatric Practice. 11 (4): 248–57. doi:10.1097/00131746-200507000-00005. PMID 16041235. Verificați datele pentru: |date= (ajutor)
Ito H, Koyama A, Higuchi T (Septembrie 2005). „Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription”. The British Journal of Psychiatry. 187 (3): 243–7. doi:10.1192/bjp.187.3.243. PMID 16135861. Verificați datele pentru: |date= (ajutor)
Vita A, De Peri L, Deste G, Sacchetti E (Noiembrie 2012). „Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies”. Translational Psychiatry. 2 (11): e190. doi:10.1038/tp.2012.116. PMC 3565772 . PMID 23168990. Verificați datele pentru: |date= (ajutor)
Radua J, Borgwardt S, Crescini A, Mataix-Cols D, Meyer-Lindenberg A, McGuire PK, Fusar-Poli P (Noiembrie 2012). „Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication”. Neuroscience and Biobehavioral Reviews. 36 (10): 2325–33. doi:10.1016/j.neubiorev.2012.07.012. PMID 22910680. Verificați datele pentru: |date= (ajutor)
Hirose S (2003). „The causes of underdiagnosing akathisia” (PDF). Schizophrenia Bulletin. 29 (3): 547–58. doi:10.1093/oxfordjournals.schbul.a007027. PMID 14609248. Arhivat (PDF) din originalul de la 15 octombrie 2015.
Moncrieff J (Iulie 2006). „Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse”. Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. Verificați datele pentru: |date= (ajutor)
Glazer WM (2000). „Expected incidence of tardive dyskinesia associated with atypical antipsychotics”. The Journal of Clinical Psychiatry. 61 Suppl 4: 21–6. PMID 10739327.
Lambert TJ (2007). „Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes”. The Journal of Clinical Psychiatry. 68 Suppl 6: 10–3. PMID 17650054.
Onrust SV, McClellan K (2001). „Perospirone”. CNS Drugs. 15 (4): 329–37; discussion 338. doi:10.2165/00023210-200115040-00006. PMID 11463136.
Nemeroff CB, Lieberman JA, Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, Kilts CD, Daniel DG (noiembrie 2005). „From clinical research to clinical practice: a 4-year review of ziprasidone”. CNS Spectrums. 10 (11 Suppl 17): 1–20. doi:10.1017/S1092852900019842. PMID 16381088.
Swainston Harrison T, Perry CM (2004). „Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder”. Drugs. 64 (15): 1715–36. doi:10.2165/00003495-200464150-00010. PMID 15257633. Arhivat din original la 10-07-2012. Verificați datele pentru: |archive-date= (ajutor)
Pickar D, Litman RE, Konicki PE, Wolkowitz OM, Breier A (1990). „Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia”. Modern Problems of Pharmacopsychiatry. 24: 124–51. doi:10.1159/000418015. ISBN 978-3-8055-5050-5. PMID 1970851.
Liemburg EJ, Knegtering H, Klein HC, Kortekaas R, Aleman A (Iunie 2012). „Antipsychotic medication and prefrontal cortex activation: a review of neuroimaging findings”. European Neuropsychopharmacology. 22 (6): 387–400. doi:10.1016/j.euroneuro.2011.12.008. PMID 22300864. Verificați datele pentru: |date= (ajutor)
McDonald C, Murphy KC (Martie 2003). „The new genetics of schizophrenia”. The Psychiatric Clinics of North America. 26 (1): 41–63. doi:10.1016/S0193-953X(02)00030-8. PMID 12683259. Verificați datele pentru: |date= (ajutor)
Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG (1995). „The role of 5-HT2A receptors in antipsychotic activity”. Life Sciences. 56 (25): 2209–22. doi:10.1016/0024-3205(95)00210-W. PMID 7791509.
Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR (octombrie 2011). „Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis”. Lancet. 378 (9799): 1306–15. doi:10.1016/S0140-6736(11)60873-8. PMID 21851976.
Citrome L (2013). „Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents”. Therapeutics and Clinical Risk Management. 9: 235–45. doi:10.2147/TCRM.S31484. PMC 3665578 . PMID 23723707.
Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valentí M, Vieta E (februarie 2010). „Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis”. The International Journal of Neuropsychopharmacology. 13 (1): 5–14. doi:10.1017/S1461145709990344. hdl:2445/53243. PMID 19638254.
Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E (mai 2012). „Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder”. European Neuropsychopharmacology. 22 (5): 339–46. doi:10.1016/j.euroneuro.2011.09.008. PMID 22000157.
Vieta E, Günther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, Åström M, Paulsson B (Septembrie 2011). „Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials” (PDF). The International Journal of Neuropsychopharmacology. 14 (8): 1029–49. doi:10.1017/S1461145711000885. hdl:2445/51726. PMID 21733231. Arhivat (PDF) din originalul de la 18 august 2017. Verificați datele pentru: |date= (ajutor)
Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (Decembrie 2010). „Second-generation antipsychotics for major depressive disorder and dysthymia”. The Cochrane Database of Systematic Reviews (12): CD008121. doi:10.1002/14651858.CD008121.pub2. PMID 21154393. Verificați datele pentru: |date= (ajutor)
Kishi T, Iwata N (Septembrie 2013). „Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials”. CNS Drugs. 27 (9): 731–41. doi:10.1007/s40263-013-0085-7. PMID 23812802. Verificați datele pentru: |date= (ajutor)
Pieters T, Majerus B (Decembrie 2011). „The introduction of chlorpromazine in Belgium and the Netherlands (1951-1968); tango between old and new treatment features”. Studies in History and Philosophy of Biological and Biomedical Sciences. 42 (4): 443–52. doi:10.1016/j.shpsc.2011.05.003. PMID 22035718. Arhivat din originalul de la 9 iulie 2017. Verificați datele pentru: |date= (ajutor)
King C, Voruganti LN (Mai 2002). „What's in a name? The evolution of the nomenclature of antipsychotic drugs”. Journal of Psychiatry & Neuroscience. 27 (3): 168–75. PMC 161646 . PMID 12066446. Verificați datele pentru: |date= (ajutor)
Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Höschl C (2006). „Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia”. CNS Drugs. 20 (5): 389–409. doi:10.2165/00023210-200620050-00004. PMID 16696579.
Gosden R, Beder S (2001). „Pharmaceutical industry agenda setting in mental health policies”. Ethical Human Sciences and Services. 3 (3): 147–59. PMID 15278977. Arhivat din originalul de la 30 aprilie 2010.
American Geriatrics Society, „Ten Things Physicians and Patients Should Question”, Choosing Wisely: an initiative of the ABIM Foundation, American Geriatrics Society, arhivat din originalul de la 1 septembrie 2013, accesat în 1 august 2013 , which cites
- American Geriatrics Society 2012 Beers Criteria Update Expert Panel (Aprilie 2012). „American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults”. Journal of the American Geriatrics Society. 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677 . PMID 22376048. Verificați datele pentru: |date= (ajutor)

nytimes.com

Wilson, Duff (2 octombrie 2010). „Side Effects May Include Lawsuits”. New York Times. Arhivat din originalul de la 23 iunie 2017.
DUFF WILSON (27 februarie 2009). „Drug Maker's E-Mail Released in Seroquel Lawsuit”. The New York Times. The New York Times Company. Arhivat din originalul de la 3 mai 2011. Accesat în 27 iulie 2012.
DUFF WILSON (27 februarie 2009). „Drug Maker's E-Mail Released in Seroquel Lawsuit”. The New York Times. The New York Times Company. Arhivat din originalul de la 3 mai 2011. Accesat în 27 iulie 2012.

oed.com

„tranquillizer, n”. Oxford English Dictionary. 1989. Accesat în 9 august 2011.

oxfordjournals.org

schizophreniabulletin.oxfordjournals.org

Hirose S (2003). „The causes of underdiagnosing akathisia” (PDF). Schizophrenia Bulletin. 29 (3): 547–58. doi:10.1093/oxfordjournals.schbul.a007027. PMID 14609248. Arhivat (PDF) din originalul de la 15 octombrie 2015.

psychiatrist.com

Stahl, SM (2003). „Describing an Atypical Antipsychotic: Receptor Binding and Its Role in Pathophysiology” (PDF). Prim Care Companion J Clin Psychiatry. 5 (Suppl. 3): 9–13. Arhivat (PDF) din originalul de la 16 octombrie 2013.

psychiatryonline.org

„PsychiatryOnline | Guidelines”.

focus.psychiatryonline.org

„Atypical Antipsychotics: Mechanism of Action” (PDF). FOCUS: The Journal of Lifelong Learning in Psychiatry. 2 (1): 48–58. Ianuarie 2004. Arhivat din original (PDF) la 22-02-2014. Verificați datele pentru: |date=, |archive-date= (ajutor)

rcpsych.org

apt.rcpsych.org

Medford N, Sierra M, Baker D, David A (2005). „Understanding and treating depersonalisation disorder”. Advances in Psychiatric Treatment. 11 (2): 92–100. doi:10.1192/apt.11.2.92. Arhivat din originalul de la 16 iulie 2011.

reuters.com

„UK study warns against antipsychotics for dementia”. reuters. 12 noiembrie 2009. Arhivat din originalul de la 20 iulie 2014. Accesat în 7 mai 2013. Verificați datele pentru: |access-date= (ajutor)

springerlink.com

Healy D (2008). „The intersection of psychopharmacology and psychiatry in the second half of the twentieth century”. În Wallace, Edwin R., Gach, John. History of Psychiatry and Medical Psychology. Boston, MA: Springer US. p. 421. ISBN 978-0-387-34707-3. Accesat în 9 august 2011. ^{[nefuncțională]}

theguardian.com

James, Adam (2 martie 2008). „Myth of the antipsychotic”. The Guardian. Guardian News and Media Limited. Arhivat din originalul de la 8 ianuarie 2014. Accesat în 27 iulie 2012.

ub.edu

diposit.ub.edu

Vieta E, Günther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, Åström M, Paulsson B (Septembrie 2011). „Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials” (PDF). The International Journal of Neuropsychopharmacology. 14 (8): 1029–49. doi:10.1017/S1461145711000885. hdl:2445/51726. PMID 21733231. Arhivat (PDF) din originalul de la 18 august 2017. Verificați datele pentru: |date= (ajutor)

uni.lu

orbilu.uni.lu

Pieters T, Majerus B (Decembrie 2011). „The introduction of chlorpromazine in Belgium and the Netherlands (1951-1968); tango between old and new treatment features”. Studies in History and Philosophy of Biological and Biomedical Sciences. 42 (4): 443–52. doi:10.1016/j.shpsc.2011.05.003. PMID 22035718. Arhivat din originalul de la 9 iulie 2017. Verificați datele pentru: |date= (ajutor)

uow.edu.au

Gosden R, Beder S (2001). „Pharmaceutical industry agenda setting in mental health policies”. Ethical Human Sciences and Services. 3 (3): 147–59. PMID 15278977. Arhivat din originalul de la 30 aprilie 2010.

washingtonpost.com

Hilzenrath, David S. (16 ianuarie 2010). „Justice suit accuses Johnson & Johnson of paying kickbacks”. The Washington Post. Arhivat din originalul de la 10 noiembrie 2012. Accesat în 17 ianuarie 2010.

web.archive.org

Finkel RF, Clark MA, Cubeddu LX (2009). Pharmacology (în engleză). Lippincott Williams & Wilkins. p. 151. ISBN 9780781771559. Arhivat din originalul de la 1 aprilie 2017.
„American Psychiatric Association Five Things Physicians and Patients Should Question”. Choosing Wisely. Arhivat din originalul de la 3 decembrie 2013. Accesat în 23 septembrie 2013.
Antipsychotic medications for psychotic disorders Arhivat în 20 d.Hr., la Wayback Machine. Organizația Mondială a Sănătății 2012 Accesat pe 20 octombrie 2017
„Psychosis and schizophrenia in adults (CG178)”. Arhivat din originalul de la 4 martie 2014.
„NICE Treatment Guidance 2014”. Arhivat din originalul de la 13 august 2014. Accesat în 7 august 2014. Verificați datele pentru: |access-date= (ajutor)
Lowes R. „Lurasidone Approved for Bipolar Depression”. Medscape. Arhivat din originalul de la 2 octombrie 2013. Accesat în 2 octombrie 2013.
The Royal College of Psychiatrists & The British Psychological Society (2003).Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care (PDF). London: Gaskell and the British Psychological Society.^{[necesită pagina]} Arhivat în 27 d.Hr., la Wayback Machine.
AMDA – The Society for Post-Acute and Long-Term Care Medicine (februarie 2014), „Ten Things Physicians and Patients Should Question”, Choosing Wisely: an initiative of the ABIM Foundation, AMDA – The Society for Post-Acute and Long-Term Care Medicine, arhivat din originalul de la 13 septembrie 2014, accesat în 20 aprilie 2015 .
„Evidence Lacking to Support Many Off-label Uses of Atypical Antipsychotics” (Press release). Agency for Healthcare Research and Quality. 17 ianuarie 2007. Arhivat din originalul de la 25 februarie 2013. Accesat în 29 iulie 2013.
American Psychiatric Association (septembrie 2013), „Five Things Physicians and Patients Should Question”, Choosing Wisely: an initiative of the ABIM Foundation, American Psychiatric Association, arhivat din originalul de la 3 decembrie 2013, accesat în 30 decembrie 2013 , which cites
- Association, American Psychiatric (2006). Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition. 1. doi:10.1176/appi.books.9780890423363.45859. ISBN 978-0-89042-336-3.
- Moore DP, Puri BK (2012). Textbook of Clinical Neuropsychiatry and Behavioral Neuroscience, Third Edition (în engleză). CRC Press. p. 791. ISBN 9781444164947. Arhivat din originalul de la 25 noiembrie 2017.
- Medford N, Sierra M, Baker D, David A (2005). „Understanding and treating depersonalisation disorder”. Advances in Psychiatric Treatment. 11 (2): 92–100. doi:10.1192/apt.11.2.92. Arhivat din originalul de la 16 iulie 2011.
- Hirose S (2003). „The causes of underdiagnosing akathisia” (PDF). Schizophrenia Bulletin. 29 (3): 547–58. doi:10.1093/oxfordjournals.schbul.a007027. PMID 14609248. Arhivat (PDF) din originalul de la 15 octombrie 2015.
- „Atypical Antipsychotics: Mechanism of Action” (PDF). FOCUS: The Journal of Lifelong Learning in Psychiatry. 2 (1): 48–58. Ianuarie 2004. Arhivat din original (PDF) la 22-02-2014. Verificați datele pentru: |date=, |archive-date= (ajutor)
- Stahl, SM (2003). „Describing an Atypical Antipsychotic: Receptor Binding and Its Role in Pathophysiology” (PDF). Prim Care Companion J Clin Psychiatry. 5 (Suppl. 3): 9–13. Arhivat (PDF) din originalul de la 16 octombrie 2013.
- Vieta E, Günther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, Åström M, Paulsson B (Septembrie 2011). „Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials” (PDF). The International Journal of Neuropsychopharmacology. 14 (8): 1029–49. doi:10.1017/S1461145711000885. hdl:2445/51726. PMID 21733231. Arhivat (PDF) din originalul de la 18 august 2017. Verificați datele pentru: |date= (ajutor)
- Pieters T, Majerus B (Decembrie 2011). „The introduction of chlorpromazine in Belgium and the Netherlands (1951-1968); tango between old and new treatment features”. Studies in History and Philosophy of Biological and Biomedical Sciences. 42 (4): 443–52. doi:10.1016/j.shpsc.2011.05.003. PMID 22035718. Arhivat din originalul de la 9 iulie 2017. Verificați datele pentru: |date= (ajutor)
- Owens DG (13 aprilie 1999). A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge University Press. p. 12. ISBN 978-0-521-63353-6. Arhivat din originalul de la 18 martie 2016.
- James, Adam (2 martie 2008). „Myth of the antipsychotic”. The Guardian. Guardian News and Media Limited. Arhivat din originalul de la 8 ianuarie 2014. Accesat în 27 iulie 2012.
- Nick Triggle (12 noiembrie 2009). „Dementia drug use 'killing many'”. BBC. Arhivat din originalul de la 26 aprilie 2013. Accesat în 7 mai 2013. Verificați datele pentru: |access-date= (ajutor)
- „UK study warns against antipsychotics for dementia”. reuters. 12 noiembrie 2009. Arhivat din originalul de la 20 iulie 2014. Accesat în 7 mai 2013. Verificați datele pentru: |access-date= (ajutor)
- Hilzenrath, David S. (16 ianuarie 2010). „Justice suit accuses Johnson & Johnson of paying kickbacks”. The Washington Post. Arhivat din originalul de la 10 noiembrie 2012. Accesat în 17 ianuarie 2010.
- Wilson, Duff (2 octombrie 2010). „Side Effects May Include Lawsuits”. New York Times. Arhivat din originalul de la 23 iunie 2017.
- DUFF WILSON (27 februarie 2009). „Drug Maker's E-Mail Released in Seroquel Lawsuit”. The New York Times. The New York Times Company. Arhivat din originalul de la 3 mai 2011. Accesat în 27 iulie 2012.
- DUFF WILSON (27 februarie 2009). „Drug Maker's E-Mail Released in Seroquel Lawsuit”. The New York Times. The New York Times Company. Arhivat din originalul de la 3 mai 2011. Accesat în 27 iulie 2012.
- Gosden R, Beder S (2001). „Pharmaceutical industry agenda setting in mental health policies”. Ethical Human Sciences and Services. 3 (3): 147–59. PMID 15278977. Arhivat din originalul de la 30 aprilie 2010.
- American Psychiatric Association (Septembrie 2013), „Five Things Physicians and Patients Should Question”, Choosing Wisely: an initiative of the ABIM Foundation, American Psychiatric Association, arhivat din originalul de la 3 decembrie 2013, accesat în 30 decembrie 2013 Verificați datele pentru: |date= (ajutor), care citează
  - Association, American Psychiatric (2006). „Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias, Second Edition”. APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches. 1. doi:10.1176/appi.books.9780890423967.152139. ISBN 978-0-89042-336-3.
  - American Geriatrics Society, „Ten Things Physicians and Patients Should Question”, Choosing Wisely: an initiative of the ABIM Foundation, American Geriatrics Society, arhivat din originalul de la 1 septembrie 2013, accesat în 1 august 2013 , which cites
    - American Geriatrics Society 2012 Beers Criteria Update Expert Panel (Aprilie 2012). „American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults”. Journal of the American Geriatrics Society. 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677 . PMID 22376048. Verificați datele pentru: |date= (ajutor)

who.int

Antipsychotic medications for psychotic disorders Arhivat în 20 d.Hr., la Wayback Machine. Organizația Mondială a Sănătății 2012 Accesat pe 20 octombrie 2017

wkhealth.com

content.wkhealth.com

Swainston Harrison T, Perry CM (2004). „Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder”. Drugs. 64 (15): 1715–36. doi:10.2165/00003495-200464150-00010. PMID 15257633. Arhivat din original la 10-07-2012. Verificați datele pentru: |archive-date= (ajutor)

worldcat.org

Hippius, H. (1 martie 1989). „The history of clozapine”. Psychopharmacology (în engleză). 99 (1): S3–S5. doi:10.1007/BF00442551. ISSN 0033-3158.